Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00373256 · ClinicalTrials.gov registry record · Phase 3
A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer
A Phase 3 study of Breast Neoplasms, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 488
- Enrollment target
- 20
- Study locations
NCT00373256 is a Phase 3 study of Breast Neoplasms that has completed, run by Pfizer. The registered enrollment target is 488 participants, below the 564-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (13% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT00373256, a Phase 3 study of Breast Neoplasms, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 488 participants
- Enrollment target
- 20
- Study locations
Study Summary
To compare treatment with SU011248 plus paclitaxel versus bevacizumab plus paclitaxel to determine which treatment works better against breast cancer
Conditions Studied
Interventions
- DRUG Sunitinib
- DRUG bevacizumab
- DRUG paclitaxel
Study Locations (20)
Alabama
- Pfizer Investigational Site - Bessemer
- Pfizer Investigational Site - Birmingham
- Pfizer Investigational Site - Birmingham
- Pfizer Investigational Site - Birmingham
- Pfizer Investigational Site - Birmingham
- Pfizer Investigational Site - Birmingham
- Pfizer Investigational Site - Daphne
- Pfizer Investigational Site - Mobile
- Pfizer Investigational Site - Mobile
California
- Pfizer Investigational Site - Anaheim
- Pfizer Investigational Site - Antioch
- Pfizer Investigational Site - Antioch
- Pfizer Investigational Site - Baldwin Park
- Pfizer Investigational Site - Bellflower
- Pfizer Investigational Site - Fontana
- Pfizer Investigational Site - Fountain Valley
- Pfizer Investigational Site - Gilroy
Arizona
- Pfizer Investigational Site - Flagstaff
- Pfizer Investigational Site - Sedona
Arkansas
- Pfizer Investigational Site - Hot Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 488 participants |
| Start Date | 2006-11 |
| Est. Completion | 2011-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00373256
The ClinicalTrials.gov registry entry for NCT00373256 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 488 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 564-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (13% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Sunitinib is the first listed.
NCT00373256 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Alabama, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT00373256 about?
NCT00373256 is a clinical study titled "A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer". To compare treatment with SU011248 plus paclitaxel versus bevacizumab plus paclitaxel to determine which treatment works better against breast cancer
What is the current status of trial NCT00373256?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 488 participants. The study started on 2006-11. Estimated completion is 2011-08.
What conditions does trial NCT00373256 study?
This clinical trial studies the following conditions: Breast Neoplasms.
What interventions are being tested in trial NCT00373256?
The interventions under investigation include: Sunitinib (DRUG), bevacizumab (DRUG), paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00373256?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00373256 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RECRUITING · Phase 3
-
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RECRUITING · Phase 3
-
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
RECRUITING · Phase 3
-
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
RECRUITING · Phase 3
-
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
RECRUITING · Phase 3
-
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.